OA10983A - Comprimé à libération contrôlée de chlorhydrate d'alfuzosine. - Google Patents

Comprimé à libération contrôlée de chlorhydrate d'alfuzosine. Download PDF

Info

Publication number: OA10983A
Authority: OA; OAPI
Prior art keywords: layer; tablet according; layers; preparation; tablet
Prior art date: 1996-08-29

Application number

OA9900042A

Other languages

English (en)

French (fr)

Inventor

Ubaldo Conte

Pascal Grenier

Guy Vergnault

Alain Dufour

Francois Xavier Jarreau

Clemence Rauch-Desanti

Original Assignee

Synthelabo

Jagotec Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-29

Filing date

1999-02-26

Publication date

2003-03-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26232935&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA10983(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-08-29 Priority claimed from FR9610551A external-priority patent/FR2752737B1/fr

1999-02-26 Application filed by Synthelabo, Jagotec Ag filed Critical Synthelabo

2003-03-04 Publication of OA10983A publication Critical patent/OA10983A/fr

Links

238000013270 controlled release Methods 0.000 title claims abstract description 10
229960003103 alfuzosin hydrochloride Drugs 0.000 title claims description 44
YTNKWDJILNVLGX-UHFFFAOYSA-N alfuzosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 YTNKWDJILNVLGX-UHFFFAOYSA-N 0.000 title claims description 44
239000008187 granular material Substances 0.000 claims abstract description 93
238000002360 preparation method Methods 0.000 claims abstract description 65
239000013543 active substance Substances 0.000 claims abstract description 50
239000000203 mixture Substances 0.000 claims abstract description 41
230000004888 barrier function Effects 0.000 claims abstract description 22
230000008961 swelling Effects 0.000 claims abstract description 20
WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 claims abstract description 14
230000006835 compression Effects 0.000 claims abstract description 13
238000007906 compression Methods 0.000 claims abstract description 13
229920001477 hydrophilic polymer Polymers 0.000 claims abstract description 12
239000000126 substance Substances 0.000 claims abstract description 11
210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 9
239000007788 liquid Substances 0.000 claims abstract description 7
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 26
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 26
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 26
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 26
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 11
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 11
239000008108 microcrystalline cellulose Substances 0.000 claims description 11
229940016286 microcrystalline cellulose Drugs 0.000 claims description 11
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 9
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 9
229930195725 Mannitol Natural products 0.000 claims description 9
229960004607 alfuzosin Drugs 0.000 claims description 9
239000008101 lactose Substances 0.000 claims description 9
239000000594 mannitol Substances 0.000 claims description 9
235000010355 mannitol Nutrition 0.000 claims description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 6
239000011248 coating agent Substances 0.000 claims description 6
238000000576 coating method Methods 0.000 claims description 6
239000012530 fluid Substances 0.000 claims description 6
239000000546 pharmaceutical excipient Substances 0.000 claims description 6
230000035515 penetration Effects 0.000 claims description 5
239000001856 Ethyl cellulose Substances 0.000 claims description 4
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 4
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
229920002472 Starch Polymers 0.000 claims description 4
239000003085 diluting agent Substances 0.000 claims description 4
235000019325 ethyl cellulose Nutrition 0.000 claims description 4
229920001249 ethyl cellulose Polymers 0.000 claims description 4
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
150000003839 salts Chemical class 0.000 claims description 4
235000019698 starch Nutrition 0.000 claims description 4
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
239000001768 carboxy methyl cellulose Substances 0.000 claims description 3
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims description 3
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims description 3
-1 lexylitol Substances 0.000 claims description 3
239000011734 sodium Substances 0.000 claims description 3
229910052708 sodium Inorganic materials 0.000 claims description 3
229920000856 Amylose Polymers 0.000 claims description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
229920001661 Chitosan Polymers 0.000 claims description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
229920000926 Galactomannan Polymers 0.000 claims description 2
229920001503 Glucan Polymers 0.000 claims description 2
229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
229920000057 Mannan Polymers 0.000 claims description 2
229920002732 Polyanhydride Polymers 0.000 claims description 2
229920002305 Schizophyllan Polymers 0.000 claims description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
239000004141 Sodium laurylsulphate Substances 0.000 claims description 2
229920002125 Sokalan® Polymers 0.000 claims description 2
150000001252 acrylic acid derivatives Chemical class 0.000 claims description 2
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
235000010443 alginic acid Nutrition 0.000 claims description 2
239000000783 alginic acid Substances 0.000 claims description 2
229920000615 alginic acid Polymers 0.000 claims description 2
229960001126 alginic acid Drugs 0.000 claims description 2
150000004781 alginic acids Chemical class 0.000 claims description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 2
239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
229920001525 carrageenan Polymers 0.000 claims description 2
235000010418 carrageenan Nutrition 0.000 claims description 2
229920001577 copolymer Polymers 0.000 claims description 2
YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 claims description 2
125000005456 glyceride group Chemical group 0.000 claims description 2
239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
230000002209 hydrophobic effect Effects 0.000 claims description 2
235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 2
229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 2
239000000787 lecithin Substances 0.000 claims description 2
235000010445 lecithin Nutrition 0.000 claims description 2
FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims description 2
LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 claims description 2
150000002734 metacrylic acid derivatives Chemical class 0.000 claims description 2
229920000609 methyl cellulose Polymers 0.000 claims description 2
XJRBAMWJDBPFIM-UHFFFAOYSA-N methyl vinyl ether Chemical class COC=C XJRBAMWJDBPFIM-UHFFFAOYSA-N 0.000 claims description 2
239000001923 methylcellulose Substances 0.000 claims description 2
150000002942 palmitic acid derivatives Chemical class 0.000 claims description 2
239000001814 pectin Substances 0.000 claims description 2
229920001277 pectin Polymers 0.000 claims description 2
235000010987 pectin Nutrition 0.000 claims description 2
239000008180 pharmaceutical surfactant Substances 0.000 claims description 2
229920000136 polysorbate Polymers 0.000 claims description 2
229940068965 polysorbates Drugs 0.000 claims description 2
229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
239000000600 sorbitol Substances 0.000 claims description 2
235000010356 sorbitol Nutrition 0.000 claims description 2
239000008107 starch Substances 0.000 claims description 2
239000001993 wax Substances 0.000 claims description 2
229920001285 xanthan gum Polymers 0.000 claims description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 claims 1
239000007884 disintegrant Substances 0.000 claims 1
229920001308 poly(aminoacid) Polymers 0.000 claims 1
238000002203 pretreatment Methods 0.000 claims 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 claims 1
URLJMZWTXZTZRR-UHFFFAOYSA-N sodium myristyl sulfate Chemical compound CCCCCCCCCCCCCCOS(O)(=O)=O URLJMZWTXZTZRR-UHFFFAOYSA-N 0.000 claims 1
239000010410 layer Substances 0.000 description 177
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 46
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 24
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 23
235000019359 magnesium stearate Nutrition 0.000 description 23
238000000034 method Methods 0.000 description 23
229920000036 polyvinylpyrrolidone Polymers 0.000 description 21
239000001267 polyvinylpyrrolidone Substances 0.000 description 21
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 21
239000008119 colloidal silica Substances 0.000 description 20
238000004519 manufacturing process Methods 0.000 description 18
239000000825 pharmaceutical preparation Substances 0.000 description 16
239000000843 powder Substances 0.000 description 12
238000012360 testing method Methods 0.000 description 10
239000004359 castor oil Substances 0.000 description 9
235000019438 castor oil Nutrition 0.000 description 9
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 9
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
238000007922 dissolution test Methods 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
239000000243 solution Substances 0.000 description 4
OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 3
239000002775 capsule Substances 0.000 description 3
210000004051 gastric juice Anatomy 0.000 description 3
239000008213 purified water Substances 0.000 description 3
238000009736 wetting Methods 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
UKMSUNONTOPOIO-UHFFFAOYSA-M behenate Chemical compound CCCCCCCCCCCCCCCCCCCCCC([O-])=O UKMSUNONTOPOIO-UHFFFAOYSA-M 0.000 description 2
229940116224 behenate Drugs 0.000 description 2
239000013060 biological fluid Substances 0.000 description 2
239000012738 dissolution medium Substances 0.000 description 2
235000019441 ethanol Nutrition 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000005259 measurement Methods 0.000 description 2
IBIKHMZPHNKTHM-RDTXWAMCSA-N merck compound 25 Chemical compound C1C[C@@H](C(O)=O)[C@H](O)CN1C(C1=C(F)C=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C1CC1 IBIKHMZPHNKTHM-RDTXWAMCSA-N 0.000 description 2
230000000877 morphologic effect Effects 0.000 description 2
OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
101100004297 Caenorhabditis elegans bet-1 gene Proteins 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000000872 buffer Substances 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
210000001630 jejunum Anatomy 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
229960000502 poloxamer Drugs 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
238000005070 sampling Methods 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000002356 single layer Substances 0.000 description 1
IJRHDFLHUATAOS-DPMBMXLASA-M sodium ricinoleate Chemical compound [Na+].CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O IJRHDFLHUATAOS-DPMBMXLASA-M 0.000 description 1
229960002920 sorbitol Drugs 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

OA9900042A 1996-08-29 1999-02-26 Comprimé à libération contrôlée de chlorhydrate d'alfuzosine. OA10983A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9610551A FR2752737B1 (fr)	1996-08-29	1996-08-29	Comprime a liberation controlee de chlorhydrate d'alfuzosine
FR9704386		1997-04-10

Publications (1)

Publication Number	Publication Date
OA10983A true OA10983A (fr)	2003-03-04

Family

ID=26232935

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA9900042A OA10983A (fr)	1996-08-29	1999-02-26	Comprimé à libération contrôlée de chlorhydrate d'alfuzosine.

Country Status (36)

Country	Link
US (1)	US6149940A (de)
EP (1)	EP0938318B1 (de)
JP (1)	JP3797388B2 (de)
KR (1)	KR100364328B1 (de)
CN (2)	CN1155382C (de)
AP (1)	AP1107A (de)
AR (1)	AR009312A1 (de)
AT (1)	ATE200864T1 (de)
AU (1)	AU724490B2 (de)
BG (1)	BG63768B1 (de)
BR (1)	BR9713237B1 (de)
CA (1)	CA2264250C (de)
CO (1)	CO4920217A1 (de)
CY (1)	CY2284B1 (de)
CZ (1)	CZ295066B6 (de)
DE (1)	DE69704712T2 (de)
DK (1)	DK0938318T3 (de)
EE (1)	EE03855B1 (de)
ES (1)	ES2159400T3 (de)
GR (1)	GR3036291T3 (de)
HU (1)	HU228007B1 (de)
IL (1)	IL128146A (de)
IS (1)	IS2091B (de)
MX (1)	MXPA99001958A (de)
NO (1)	NO326206B1 (de)
NZ (1)	NZ334018A (de)
OA (1)	OA10983A (de)
PL (1)	PL191546B1 (de)
PT (1)	PT938318E (de)
RU (1)	RU2183459C2 (de)
SI (1)	SI0938318T1 (de)
SK (1)	SK284388B6 (de)
TR (1)	TR199900289T2 (de)
TW (1)	TW522023B (de)
UA (1)	UA69374C2 (de)
WO (1)	WO1998008515A1 (de)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6720471B1 (en)	1998-04-28	2004-04-13	The Procter & Gamble Company	Absorbent articles having reduced rewet with distribution materials positioned underneath storage material
US7022683B1 (en)	1998-05-13	2006-04-04	Carrington Laboratories, Inc.	Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
FR2784583B1 (fr) *	1998-10-16	2002-01-25	Synthelabo	Composition pharmaceutique a residence gastrique et a liberation controlee
ES2270982T3 (es)	2000-02-04	2007-04-16	Depomed, Inc.	Forma de dosificacion de nucleo y carcasa que se aproxima a una liberacion del farmaco de orden cero.
AR030557A1 (es)	2000-04-14	2003-08-27	Jagotec Ag	Una tableta en multicapa de liberacion controlada y metodo de tratamiento
FR2820318B1 (fr) *	2001-02-08	2005-12-23	Ellipse Pharmaceuticals	Procede de fabrication d'un comprime flottant incluant un principe actif et comprime obtenu
FR2820319B3 (fr) *	2001-02-08	2003-12-05	Ellipse Pharmaceuticals	Procede de fabrication d'un comprime flottant incluant de l'alfuzosine et comprime obtenu
US7494669B2 (en)	2001-02-28	2009-02-24	Carrington Laboratories, Inc.	Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
US6777000B2 (en)	2001-02-28	2004-08-17	Carrington Laboratories, Inc.	In-situ gel formation of pectin
US7163696B2 (en) *	2001-10-11	2007-01-16	Pfizer Inc.	Pharmaceutical formulations
US7008979B2 (en)	2002-04-30	2006-03-07	Hydromer, Inc.	Coating composition for multiple hydrophilic applications
US6852238B2 (en) *	2002-08-29	2005-02-08	Steller Technology Company	Layered tablet water treatment compositions and method of use
US7309444B2 (en) *	2002-08-29	2007-12-18	Stellar Technology Company	Layered tablet water treatment compositions and method of use
SI1551372T1 (en)	2002-09-20	2018-08-31	Alpharma Pharmaceuticals Llc	SUBVENCATION DATA AND RELATED CONSTRUCTIONS AND PROCEDURES
EP1556014A1 (de) *	2002-10-22	2005-07-27	Ranbaxy Laboratories, Ltd.	Alfuzosin enthaltende zusammensetzungen mit verzlängerter freisetzung
MX2007001138A (es) *	2004-07-29	2007-04-19	Sanofi Aventis	Comprimido farmaceutico multicapa para la liberacion controlada de ingredientes activos con solubilidad muy dependiente del ph.
FR2874325B1 (fr) *	2004-08-19	2006-10-20	Sanofi Synthelabo	Composition pharmaceutique sous forme de comprime a residence gastrique contenant de l'alfuzosine
US20060062846A1 (en) *	2004-09-17	2006-03-23	Cimex Pharma Ag	Alfuzosin tablets and synthesis
US20060062845A1 (en) *	2004-09-17	2006-03-23	Cimex Pharma Ag	Alfuzosin tablets and synthesis
ITMI20050391A1 (it) *	2005-03-11	2006-09-12	Ph & T S P A	Formulazioni a rilascio controllato di alfuzosin
US9198608B2 (en)	2005-04-28	2015-12-01	Proteus Digital Health, Inc.	Communication system incorporated in a container
US8802183B2 (en)	2005-04-28	2014-08-12	Proteus Digital Health, Inc.	Communication system with enhanced partial power source and method of manufacturing same
US8912908B2 (en)	2005-04-28	2014-12-16	Proteus Digital Health, Inc.	Communication system with remote activation
US8836513B2 (en)	2006-04-28	2014-09-16	Proteus Digital Health, Inc.	Communication system incorporated in an ingestible product
EP2392258B1 (de)	2005-04-28	2014-10-08	Proteus Digital Health, Inc.	Pharma-Informatiksystem
MX2007013725A (es)	2005-05-05	2008-04-09	Sensient Flavors Inc	Produccion de beta-glucanos y mananos.
US20090238776A1 (en) *	2005-11-09	2009-09-24	Arif Ali Baig	Oral Care Compositions and Methods
US20070129460A1 (en) *	2005-11-09	2007-06-07	Jayanth Rajaiah	Denture adhesive articles
US20070185237A1 (en) *	2005-11-09	2007-08-09	Jayanth Rajaiah	Denture adhesive articles
US7834066B2 (en) *	2005-11-09	2010-11-16	The Procter & Gamble Company	Denture adhesive articles
US20070185232A1 (en) *	2005-11-09	2007-08-09	Jayanth Rajaiah	Denture adhesive articles
US20070185233A1 (en) *	2005-11-09	2007-08-09	Jayanth Rajaiah	Denture adhesive articles
US20070185236A1 (en) *	2005-11-09	2007-08-09	Jayanth Rajaiah	Denture adhesive compositions
US20070185235A1 (en) *	2005-11-09	2007-08-09	Jayanth Rajaiah	Denture adhesive compositions
WO2007080509A2 (en)	2006-01-12	2007-07-19	Wockhardt Ltd	Sustained release compositions of alfuzosin
KR20140018439A (ko)	2006-05-02	2014-02-12	프로테우스 디지털 헬스, 인코포레이티드	환자 주문형 치료법
EP2719378B1 (de)	2006-06-19	2016-08-31	Alpharma Pharmaceuticals LLC	Pharmazeutische Zusammensetzungen
US20080003286A1 (en) *	2006-06-29	2008-01-03	Sathya Narayana Vemula	Sustained delivery alfuzosin compositions
WO2008041553A1 (en)	2006-09-26	2008-04-10	Astellas Pharma Inc.	Tacrolimus sustained-release preparation
US20080095844A1 (en) *	2006-10-23	2008-04-24	Rajhans Sujay Kamalakar	Sustained release pharmaceutical compositions of alfuzosin and process for preparation thereof
JP5916277B2 (ja)	2006-10-25	2016-05-11	プロテウスデジタルヘルス，インコーポレイテッド	摂取可能な制御活性化識別子
WO2008063626A2 (en)	2006-11-20	2008-05-29	Proteus Biomedical, Inc.	Active signal processing personal health signal receivers
US20080138412A1 (en) *	2006-12-06	2008-06-12	Fu-Yung Lin	Sustained release alfuzosin hydrochl formulation and method for their production
US20080160081A1 (en) *	2006-12-11	2008-07-03	Mutual Pharmaceutical Company, Inc.	Alfuzosin formulations, methods of making, and methods of use
US20100092556A1 (en) *	2006-12-11	2010-04-15	Kristin Arnold	Alfuzosin formulations, methods of making, and methods of use
EP2119442A4 (de) *	2006-12-28	2010-12-15	Astellas Pharma Inc	Pharmazeutische zusammensetzung von tacrolimus mit verzögerter freisetzung
DK3785599T3 (da)	2007-02-01	2022-11-07	Otsuka Pharma Co Ltd	Spiselige eventmarkersystemer
CA3000257C (en)	2007-02-14	2020-04-28	Proteus Digital Health, Inc.	In-body power source having high surface area electrode
WO2008102235A1 (en) *	2007-02-20	2008-08-28	Aurobindo Pharma Limited	Controlled release formulations of alfuzosin
US8932221B2 (en)	2007-03-09	2015-01-13	Proteus Digital Health, Inc.	In-body device having a multi-directional transmitter
EP2063771A1 (de)	2007-03-09	2009-06-03	Proteus Biomedical, Inc.	Körperintegrierte vorrichtung mit ausfahrbarer antenne
US8540632B2 (en)	2007-05-24	2013-09-24	Proteus Digital Health, Inc.	Low profile antenna for in body device
FI2192946T3 (fi)	2007-09-25	2022-11-30		Elimistön sisäinen laite, jossa on virtuaalinen dipolisignaalinvahvistus
US8623418B2 (en)	2007-12-17	2014-01-07	Alpharma Pharmaceuticals Llc	Pharmaceutical composition
ES2840773T3 (es)	2008-03-05	2021-07-07	Otsuka Pharma Co Ltd	Sistemas y marcadores de eventos ingeribles de comunicación multimodo
WO2009149029A2 (en) *	2008-06-04	2009-12-10	The Procter & Gamble Company	Denture adhesive compositions and methods
US20110009715A1 (en)	2008-07-08	2011-01-13	David O' Reilly	Ingestible event marker data framework
JP5715564B2 (ja)	2008-08-13	2015-05-07	プロテウスデジタルヘルス，インコーポレイテッド	摂取可能デバイスおよびそれを生成する方法
US20100233259A1 (en) *	2008-12-12	2010-09-16	Pascal Grenier	Dosage form of ropinirole
JP2012514799A (ja)	2009-01-06	2012-06-28	プロテウスバイオメディカルインコーポレイテッド	摂取に関連するバイオフィードバックおよび個別薬物療法の方法およびシステム
US8597186B2 (en)	2009-01-06	2013-12-03	Proteus Digital Health, Inc.	Pharmaceutical dosages delivery system
WO2010083360A2 (en) *	2009-01-16	2010-07-22	Mutual Pharmaceutical Company, Inc.	Controlled-release formulations
US8540664B2 (en)	2009-03-25	2013-09-24	Proteus Digital Health, Inc.	Probablistic pharmacokinetic and pharmacodynamic modeling
SG10201810784SA (en)	2009-04-28	2018-12-28	Proteus Digital Health Inc	Highly Reliable Ingestible Event Markers And Methods For Using The Same
EP2432458A4 (de)	2009-05-12	2014-02-12	Proteus Digital Health Inc	Einnehmbarer ereignismarker mit verzehrbarem bestandteil
TWI517050B (zh)	2009-11-04	2016-01-11	普羅托斯數位健康公司	供應鏈管理之系統
CN107411973A (zh)	2010-03-10	2017-12-01	宝洁公司	义齿粘合剂组合物
JP5849947B2 (ja)	2010-03-29	2016-02-03	アステラス製薬株式会社	放出制御医薬組成物
SG10201502720VA (en)	2010-04-07	2015-05-28	Proteus Digital Health Inc	Miniature ingestible device
WO2011124953A2 (en) *	2010-04-07	2011-10-13	Lupin Limited	Controlled release pharmaceutical compositions of tapentadol
TWI557672B (zh)	2010-05-19	2016-11-11	波提亞斯數位康健公司	用於從製造商跟蹤藥物直到患者之電腦系統及電腦實施之方法、用於確認將藥物給予患者的設備及方法、患者介面裝置
EP2642983A4 (de)	2010-11-22	2014-03-12	Proteus Digital Health Inc	Einnehmbare vorrichtung mit einem pharmazeutischen produkt
CN102475690B (zh) *	2010-11-30	2016-06-01	安国药品株式会社	内含盐酸阿夫唑嗪的缓释片剂
US9756874B2 (en)	2011-07-11	2017-09-12	Proteus Digital Health, Inc.	Masticable ingestible product and communication system therefor
WO2015112603A1 (en)	2014-01-21	2015-07-30	Proteus Digital Health, Inc.	Masticable ingestible product and communication system therefor
BR112014001397A2 (pt)	2011-07-21	2017-02-21	Proteus Biomedical Inc	dispositivo, sistema e método de comunicação móvel
US9235683B2 (en)	2011-11-09	2016-01-12	Proteus Digital Health, Inc.	Apparatus, system, and method for managing adherence to a regimen
CN104487347B (zh)	2012-07-23	2017-09-01	普罗秋斯数字健康公司	用于制造包括电子器件的片剂的方法和系统
DK2910013T3 (en)	2012-10-18	2018-08-06	Proteus Digital Health Inc	Apparatus, system and method for adaptive optimization for power output and transmit power in a power source for a communication device
TWI659994B (zh)	2013-01-29	2019-05-21	美商普羅托斯數位健康公司	高度可膨脹之聚合型薄膜及包含彼之組成物
JP5941240B2 (ja)	2013-03-15	2016-06-29	プロテウスデジタルヘルス，インコーポレイテッド	金属検出器装置、システム、および方法
WO2014197402A1 (en)	2013-06-04	2014-12-11	Proteus Digital Health, Inc.	System, apparatus and methods for data collection and assessing outcomes
US9796576B2 (en)	2013-08-30	2017-10-24	Proteus Digital Health, Inc.	Container with electronically controlled interlock
US10084880B2 (en)	2013-11-04	2018-09-25	Proteus Digital Health, Inc.	Social media networking based on physiologic information
US11051543B2 (en)	2015-07-21	2021-07-06	Otsuka Pharmaceutical Co. Ltd.	Alginate on adhesive bilayer laminate film
WO2017078557A1 (ru) *	2015-11-05	2017-05-11	Анатолий Викторович ЗАЗУЛЯ	Изготовление таблетки с механизмом повышения терапевтической эффективности лекарственного средства нанодозой аналога
BR112019000861B1 (pt)	2016-07-22	2020-10-27	Proteus Digital Health, Inc	dispositivo eletrônico
CA3041041A1 (en)	2016-10-26	2018-05-03	Proteus Digital Health, Inc.	Methods for manufacturing capsules with ingestible event markers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2582513B1 (fr) *	1985-05-28	1988-08-05	Synthelabo	Compositions pharmaceutiques contenant de l'alfuzosine
IT1188212B (it) *	1985-12-20	1988-01-07	Paolo Colombo	Sistema per il rilascio a velocita' controllata di sostanze attive
IT1237904B (it) *	1989-12-14	1993-06-18	Ubaldo Conte	Compresse a rilascio a velocita' controllata delle sostanze attive
GB9311191D0 (en) *	1993-05-29	1993-07-14	Danbiosyst Uk	Controlled release drug formulation
FR2717388B1 (fr) *	1994-03-21	1996-11-22	Synthelabo	Formes galéniques à libération prolongée du chlorhydrate d'alfuzosine.

1997
- 1997-08-22 KR KR1019997001666A patent/KR100364328B1/ko not_active Expired - Lifetime
- 1997-08-22 PL PL331862A patent/PL191546B1/pl unknown
- 1997-08-22 CN CNB971975582A patent/CN1155382C/zh not_active Expired - Lifetime
- 1997-08-22 CZ CZ1999655A patent/CZ295066B6/cs not_active IP Right Cessation
- 1997-08-22 CN CNB2004100422955A patent/CN100335057C/zh not_active Expired - Lifetime
- 1997-08-22 US US09/147,581 patent/US6149940A/en not_active Expired - Lifetime
- 1997-08-22 MX MXPA99001958A patent/MXPA99001958A/es active IP Right Grant
- 1997-08-22 TR TR1999/00289T patent/TR199900289T2/xx unknown
- 1997-08-22 SK SK270-99A patent/SK284388B6/sk not_active IP Right Cessation
- 1997-08-22 DK DK97937651T patent/DK0938318T3/da active
- 1997-08-22 EP EP97937651A patent/EP0938318B1/de not_active Expired - Lifetime
- 1997-08-22 HU HU9903428A patent/HU228007B1/hu unknown
- 1997-08-22 SI SI9730158T patent/SI0938318T1/xx unknown
- 1997-08-22 CA CA002264250A patent/CA2264250C/en not_active Expired - Lifetime
- 1997-08-22 EE EEP199900090A patent/EE03855B1/xx unknown
- 1997-08-22 ES ES97937651T patent/ES2159400T3/es not_active Expired - Lifetime
- 1997-08-22 AP APAP/P/1999/001470A patent/AP1107A/en active
- 1997-08-22 NZ NZ334018A patent/NZ334018A/xx not_active IP Right Cessation
- 1997-08-22 RU RU99105730/14A patent/RU2183459C2/ru active
- 1997-08-22 AT AT97937651T patent/ATE200864T1/de active
- 1997-08-22 UA UA99020755A patent/UA69374C2/uk unknown
- 1997-08-22 AU AU40201/97A patent/AU724490B2/en not_active Expired
- 1997-08-22 WO PCT/FR1997/001515 patent/WO1998008515A1/fr not_active Ceased
- 1997-08-22 BR BRPI9713237-3A patent/BR9713237B1/pt not_active IP Right Cessation
- 1997-08-22 DE DE69704712T patent/DE69704712T2/de not_active Expired - Lifetime
- 1997-08-22 IL IL12814697A patent/IL128146A/xx not_active IP Right Cessation
- 1997-08-22 PT PT97937651T patent/PT938318E/pt unknown
- 1997-08-22 JP JP51133198A patent/JP3797388B2/ja not_active Expired - Lifetime
- 1997-08-25 AR ARP970103839A patent/AR009312A1/es active IP Right Grant
- 1997-08-26 TW TW086112274A patent/TW522023B/zh not_active IP Right Cessation
- 1997-08-28 CO CO97049830A patent/CO4920217A1/es unknown
1999
- 1999-01-29 IS IS4964A patent/IS2091B/is unknown
- 1999-02-01 BG BG103138A patent/BG63768B1/bg unknown
- 1999-02-26 OA OA9900042A patent/OA10983A/fr unknown
- 1999-02-26 NO NO19990944A patent/NO326206B1/no not_active IP Right Cessation
2001
- 2001-07-26 GR GR20010401141T patent/GR3036291T3/el unknown
2002
- 2002-05-15 CY CY0200038A patent/CY2284B1/xx unknown

Also Published As

Publication number	Publication date
SI0938318T1 (en)	2001-12-31
BG63768B1 (bg)	2002-12-29
CO4920217A1 (es)	2000-05-29
ES2159400T3 (es)	2001-10-01
IS4964A (is)	1999-01-29
NZ334018A (en)	1999-06-29
AU4020197A (en)	1998-03-19
IL128146A (en)	2001-01-11
CN1155382C (zh)	2004-06-30
DE69704712D1 (de)	2001-06-07
EP0938318A1 (de)	1999-09-01
CN100335057C (zh)	2007-09-05
KR100364328B1 (ko)	2002-12-26
JP2000514462A (ja)	2000-10-31
WO1998008515A1 (fr)	1998-03-05
GR3036291T3 (en)	2001-10-31
CA2264250C (en)	2005-07-05
UA69374C2 (uk)	2004-09-15
EE03855B1 (et)	2002-10-15
EE9900090A (et)	1999-10-15
CN1228700A (zh)	1999-09-15
CY2284B1 (en)	2003-07-04
PL191546B1 (pl)	2006-06-30
CZ295066B6 (cs)	2005-05-18
NO990944L (no)	1999-04-27
DE69704712T2 (de)	2001-11-29
AP1107A (en)	2002-09-20
AP9901470A0 (en)	1999-03-31
NO990944D0 (no)	1999-02-26
RU2183459C2 (ru)	2002-06-20
EP0938318B1 (de)	2001-05-02
SK27099A3 (en)	1999-12-10
BG103138A (en)	1999-09-30
PL331862A1 (en)	1999-08-16
BR9713237B1 (pt)	2009-01-13
IL128146A0 (en)	1999-11-30
US6149940A (en)	2000-11-21
CZ65599A3 (cs)	1999-06-16
HU228007B1 (en)	2012-08-28
IS2091B (is)	2006-03-15
HUP9903428A3 (en)	2000-04-28
SK284388B6 (sk)	2005-02-04
MXPA99001958A (es)	2005-09-08
PT938318E (pt)	2001-10-30
TW522023B (en)	2003-03-01
ATE200864T1 (de)	2001-05-15
HK1020875A1 (en)	2000-05-26
DK0938318T3 (da)	2001-08-20
HUP9903428A2 (hu)	2000-02-28
BR9713237A (pt)	2000-04-04
AU724490B2 (en)	2000-09-21
KR20000035929A (ko)	2000-06-26
CN1543954A (zh)	2004-11-10
CA2264250A1 (en)	1998-03-05
NO326206B1 (no)	2008-10-20
AR009312A1 (es)	2000-04-12
TR199900289T2 (xx)	2000-12-21
JP3797388B2 (ja)	2006-07-19

Publication	Publication Date	Title
EP0938318B1 (de)	2001-05-02	Tablette mit gesteuerter freisetzung von alfuzosinhydrochlorid
EP1492511B1 (de)	2009-01-07	Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
EP1681051B1 (de)	2016-04-06	Mehrschichtige Tablette zur kontrollierten Freisetzung bestehend aus einer aktiven Schicht und einer oder mehreren Barriereschichten
CA2219475C (fr)	2002-07-09	Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
CA2463134C (fr)	2012-01-03	Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
CA2483212C (fr)	2012-10-02	Particules enrobees a liberation prolongee et comprimes les contenant
BE1014328A7 (fr)	2003-08-05	Composition pharmaceutique orale a liberation controlee.
US20070128276A1 (en)	2007-06-07	Controlled release compositions comprising nimesulide
EP1485071A2 (de)	2004-12-15	Komprimierte tabletten mit mikrokapseln mit modifizierter freisetzung
EP2276474A1 (de)	2011-01-26	Feste orale multipartikelhaltige darreichungsform mit zweifachem freisetzungsprofil
CA2378988C (fr)	2012-04-17	Composition pharmaceutique flottante comprenant une phase active et une phase non active
BE1015413A6 (fr)	2005-03-01	Systeme de delivrance orale controlee d'un medicament.
FR2752737A1 (fr)	1998-03-06	Comprime a liberation controlee de chlorhydrate d'alfuzosine
HK1020875B (en)	2001-11-23	Tablet with controlled release of alfuzosine chlorydrate
WO2006087395A1 (fr)	2006-08-24	Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
Panchal et al.	0	FORMULATION EVALUATION AND OPTIMIZATION OF NOVEL TABLET FOR COMBINATION THERAPY
FR2843881A1 (fr)	2004-03-05	Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)